Distinct genes encode 6 human receptors for IgG (hFc␥Rs), 3 of which have 2 or 3 polymorphic variants. The specificity and affinity of individual hFc␥Rs for the 4 human IgG subclasses is unknown. This information is critical for antibodybased immunotherapy which has been increasingly used in the clinics. We investigated the binding of polyclonal and monoclonal IgG1, IgG2, IgG3, and IgG4 to Fc␥RI; Fc␥RIIA, IIB, and IIC; Fc␥RIIIA and IIIB; and all known polymorphic variants. Wild-type and low-fucosylated IgG1 anti-CD20 and anti-RhD mAbs were also examined. We found that (1) IgG1 and IgG3 bind to all hFc␥Rs; (2) IgG2 bind not only to Fc␥RIIA H131 , but also, with a lower affinity, to Fc␥RIIA R131 4 Other FcRs are inserted in the outer layer of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor and contain no signaling motif. 5 FcRs have been associated with many antibodydependent diseases 6 and are key molecules in antibody-based immunotherapy. These include the treatment, for instance, of non-Hodgkin lymphomas by mouse/human chimeric IgG1 anti-CD20 antibodies 7 and the prevention of hemolytic disease of the newborn by a mixture of polyclonal IgG1 and IgG3 anti-RhD antibodies (eg, Rophylac). Therapeutic antibodies are, however, potentially harmful, as exemplified by a recent clinical trial using IgG4 anti-CD28 antibodies.
Introduction
The biological activities of antibodies depend on the interaction of their Fc portion with effector systems. These are essentially complement and cells. Antibodies bind to cells that express receptors for the Fc portion of antibodies (FcRs). FcRs exist for all classes of antibodies. They are expressed by different cell types having different biological activities, which they modulate when they are aggregated by multivalent antigen-antibody complexes. 1 Most cells express several FcRs, and different FcRs can generate different signals in a single cell, depending on their intracytoplasmic domains. Activating FcRs possess immunoreceptor tyrosinebased activation motifs (ITAMs). 2 ITAMs are present in the intracytoplasmic domain of FcR␥, a homodimeric common subunit which associates with the ligand-binding subunit of most activating FcRs. 3 They are also present in the intracytoplasmic domain of 2 single-chain activating receptors. Inhibitory FcRs are singlechain receptors that possess an immunoreceptor tyrosine-based inhibition motif (ITIM) in their intracytoplasmic domain. 4 Other FcRs are inserted in the outer layer of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor and contain no signaling motif. 5 FcRs have been associated with many antibodydependent diseases 6 and are key molecules in antibody-based immunotherapy. These include the treatment, for instance, of non-Hodgkin lymphomas by mouse/human chimeric IgG1 anti-CD20 antibodies 7 and the prevention of hemolytic disease of the newborn by a mixture of polyclonal IgG1 and IgG3 anti-RhD antibodies (eg, Rophylac). Therapeutic antibodies are, however, potentially harmful, as exemplified by a recent clinical trial using IgG4 anti-CD28 antibodies.
Four human subclasses of IgG are produced in different amounts in response to various antigens. T-dependent protein antigens elicit primarily IgG1 and IgG3 antibodies, whereas T-independent carbohydrate antigens elicit primarily IgG2 antibodies. Chronic antigen stimulation, as in allergic desensitization, elicits IgG4 antibodies. The biological activities of each subclass of IgG are poorly known. IgG receptors (Fc␥Rs) are strikingly numerous in humans. They comprise high-affinity and low-affinity receptors. 8 Both high-affinity and low-affinity Fc␥Rs bind IgGimmune complexes with a high avidity, but only high-affinity Fc␥Rs bind monomeric IgG. There is one high-affinity IgG receptor in humans, hFc␥RI (CD64), and 2 families of low-affinity IgG receptors, hFc␥RIIA, IIB, and IIC (CD32), and hFc␥RIIIA and IIIB (CD16). hFc␥RI and hFc␥RIIIA are FcR␥-associated activating receptors, hFc␥RIIA and hFc␥RIIC are single-chain activating receptors, hFc␥RIIB are single-chain inhibitory receptors, and hFc␥RIIIB are GPI-anchored receptors whose function is uncertain. 1 The multiplicity of hFc␥Rs is further increased by a series of polymorphisms in their extracellular domains (reviewed in van Sorge et al 9 ) . Two alleles of the gene encoding hFc␥RIIA generate 2 variants differing at position 131, named low-responder (H 131 ) and high-responder (R 131 ). 10 The H 131 and R 131 alleles are differentially distributed in whites, Japanese, and Chinese. 11 Two alleles of the gene-encoding hFc␥RIIIA generate 2 variants differing at position 158 (V 158 and F 158 ). 12 Two alleles of the gene-encoding hFc␥RIIIB generate 2 variants differing at 4 positions, NA1 (R 36 N 65 D 82 V 106 ) and NA2 (S 36 S 65 N 82 I 106 ), with different glycosylation patterns. 13 A point mutation (A 78 D) of the NA2 allele generates another hFc␥RIIIB variant named SH. 14 Besides, duplications of the gene-encoding hFc␥RIIIB may generate a variable number of gene copies in different individuals. A single individual may therefore express all 3 hFc␥RIIIB variants. 15 hFc␥R polymorphisms have been linked to autoimmune and infectious diseases. hFc␥RIIA R131 has been associated with an increased prevalence of nephropathy, 16 bacterial infections, 17 and possibly systemic lupus erythematosus (SLE). 18, 19 hFc␥RIIIA F158 has been linked to SLE 20 and to rheumatoid arthritis (RA). 21 hFc␥RIIIB NA1 has been linked to Wegener granulomatosis 22 and systemic vasculitis 23 and hFc␥RIIIB NA2 to SLE in Japanese people. 24 The subclass specificity of hFc␥Rs has been investigated since the 1980s, that is, at a time when the complexity of hFc␥Rs was not suspected. Some studies were performed before hFc␥Rs were cloned. Others were performed using cell lines expressing several hFc␥Rs. Several techniques with different sensitivities were used. Finally, total human serum IgG or human myeloma IgG1 were used in most studies. IgG2, IgG3, and IgG4 were rarely considered. Marked variations, 25, 26 up to 1 log, were reported in the binding affinities of human IgG for the same hFc␥R. 27, 28 Compilations of these data were nevertheless repeatedly published in reviews. 6, 9, [29] [30] [31] [32] hFc␥R polymorphisms were rarely considered in these reviews. They, however, affect the binding of IgG to hFc␥Rs. hFc␥RIIA H131 , but not hFc␥RIIA R131 , was reported to bind human IgG2, 33 but the affinity of this interaction was not determined. The effect of this polymorphism on the affinity of hFc␥RIIA for human IgG1, IgG3, and IgG4 was not investigated. A higher efficiency of IgG1 anti-CD20 therapy was observed in hFc␥RIIIA V/V 158 patients than in F/F 158 patients, and peripheral blood lymphocytes from V/V 158 donors killed more efficiently anti-CD20-coated target cells than PBLs from F/F 158 donors in antibodydependent cell-mediated cytotoxicity (ADCC) assays. 34, 35 Indeed, hFc␥RIIIA V158 has a higher affinity for monoclonal hIgG1 than hFc␥RIIIA F158 . 36 The affinity of hFc␥RIIIA F158 and hFc␥RIIIA V158 for other IgG subclasses was not investigated. The NA1 and NA2 alleles of hFc␥RIIIB were described as having similar affinities for total human IgG 37 or IgG1, but discordant results were reported for IgG3. 38 The binding properties of hFc␥RIIIB SH have not been studied.
In view of these incomplete, heterogeneous, and sometimes discrepant set of data, we undertook a systematic investigation of the binding specificity of every hFc␥R for all 4 subclasses of human IgG. These were assayed, both as monomers and as complexes, on a collection of CHO transfectants expressing comparable levels of FLAG-tagged receptors. All hFc␥Rs, including all polymorphic variants, were studied. Soluble glycosylated ectodomains of all hFc␥Rs were also produced, and their affinity for IgG subclasses was measured by surface plasmon resonance (SPR). We found that IgG1 and IgG3 bind to all hFc␥Rs, that IgG2 binds to 3 hFc␥Rs, and that IgG4 binds to 6. We found that the inhibitory receptor Fc␥RIIB has a lower affinity for IgG1, IgG2, and IgG3 than all other hFc␥Rs. We also establish a hierarchy of affinities of all hFc␥Rs and their variants for polyclonal IgG of the 4 subclasses. Our data account for the previously reported association of inflammatory diseases with hFc␥R polymorphisms and should unravel novel candidate strategies in optimization of therapeutic antibodies.
Methods

Cells and cDNAs
CHO-K1 and HEK-293T cells were purchased from ATCC (Manassas, VA), and J558L transfectants producing anti-NIP (V H mouse/C H human) chimeric IgG1, IgG2, IgG3, IgG4, and IgE from the European Collection of Cell Cultures (Salisbury, United Kingdom), and cultured as recommended. Culture reagents were obtained from Invitrogen Life Technologies (Carlsbad, CA).
Human Fc␥RIIB (Fc␥RIIB1 isoform) cDNA and mouse FcR␥-chain cDNA were previously cloned in the laboratory. Human Fc␥RI and Fc␥RIIA(R 131 ) cDNAs were from J. Van de Winkel (University Medical Center Utrecht, Utrecht, The Netherlands). Human Fc␥RIIIB (NA1, NA2, and SH) 13, 14 cDNAs were provided by S. Santoso (Institute for Clinical Immunology and Transfusion Medicine, Giessen, Germany). Blood cells from healthy donors were used as a template for mRNA extraction, cDNA synthesis, and cloning of cDNAs encoding Fc␥RIIA(H 131 ) and hFc␥RIIIA(V 158 ). 12 The latter served as template to generate cDNA encoding hFc␥RIIIA(F 158 ) by site directed mutagenesis using the Quickchange Multi Kit (Stratagene, La Jolla, CA). Human Fc␥RIIC (Fc␥RIIC1 isoform) cDNA was generated by a 2-step PCR using Fc␥RIIB1 cDNA and Fc␥RIIA(R 131 ) cDNA as templates. hFc␥RIIIA(EC domain)-hFc␥RIIB (TM ϩ IC domains) chimeric cDNA was generated similarly using Fc␥RIIIA(V 158 ) cDNA and Fc␥RIIB1 cDNA as templates. Sequencing of all cDNAs did not reveal variation compared with published data. A cDNA sequence coding for a FLAG tag was inserted immediately 3Ј of the signal sequence cleavage site in all FcR cDNAs by PCR using overlapping primers. Resulting constructs were cloned into pNT NEO (pBR322 containing a SR␣ promoter, neomycin). cDNAs corresponding to EC domains of all FcRs were cloned into p3xFLAG-CMV-14 (Sigma-Aldrich, St Louis, MO), to generate soluble FcR ectodomains linked to a 3xFLAG tag at their C-terminus. CHO-K1 stable FLAG-tagged FcR transfectants were obtained by selection in 1 mg/mL Geneticin and/or 0.5 mg/mL Zeocin (Invitrogen, Paisley, United Kingdom), and were sorted to equivalent surface expression by flow cytometry on a MoFlo (Dako, Ely, United Kingdom) or FACSAria (Becton Dickinson, Franklin Lakes, NJ).
Antibodies and reagents
FITC-mIgG1 and anti-hCD32 (clone FLI8.26) were purchased from PharMingen (San Diego, CA); anti-hCD64 (clone 10.1) from Biolegend (San Diego, CA); HRP-or FITC-labeled anti-FLAG (M2) from SigmaAldrich; PE-F(abЈ) 2 anti-human Fab-specific from Jackson Immunoresearch (West Grove, PA); neutravidin-PE from Molecular Probes (Eugene, OR); polyclonal human IgG1, IgG2, IgG3, and IgG4 from The Binding Site (Birmingham, United Kingdom); myeloma human IgG2 from SigmaAldrich; myeloma human IgG4, polyclonal human IgE, and polyclonal human IgA from Biodesign (Saco, ME); human IgE (PHP142) and anti-hCD16 (clone 3G8) from Serotec (Oxford, United Kingdom); and human IgE from Calbiochem (San Diego, CA). Anti-NIP IgGs and anti-NIP IgE were purified from cell culture supernatants as described. 39 Monoclonal mouse anti-human Fc␥RIIB/C (clone GB3) was provided by U. Jacob (SuppreMol, Munich, Germany). Monoclonal human IgG1 anti-RhD 40 antibodies, monoclonal murine-human chimeric anti-HLA-DR (based on the murine IgG2a anti-HLA-DR Lym-1 mAb 41 ), and anti-CD20 42 antibodies were provided by LFB (Lille, France): the first 106 amino acids in the light and heavy chains of the chimeric mAbs were of murine origin, the following were of human origin, these constant regions being identical to the ones of the fully human IgG1 anti-RhD mAb. Anti-RhD, anti-HLA-DR, and anti-CD20 mAbs were produced in YB2/0 cells, which have decreased levels of ␣-1,6-fucosyltransferase (generating low-fucose containing mAbs) or produced in ␣-1,6-fucosyltransferase-competent CHO cells. Anti-RhD, anti-HLA-DR, and anti-CD20 mAbs produced both in CHO and YB2/0 cells demonstrated less than 3% sialylated IgG1 by high performance capillary electrophoresis laser-induced fluorescence (HPCE-LIF; not shown). PNGase F was from New England Biolabs (Ipswich, MA) and NIP 12 -BSA-biotin from BioCat (Heidelberg, Germany).
Immunoglobulin binding assays
Monomeric. Aggregates in stock solutions of human IgG were removed by an 18-hour ultracentrifugation at 100 000g followed by OD 280 nm concentration measurement, or using Ultrafree-CL PTMK Ultracel-PL 300-kDa cutoff spin columns (Millipore, Billerica, MA; as an internal control of the experiment, 100% of IgM was retained on the column); 2 ϫ 10 5 cells were incubated with monomeric Ig at indicated concentrations for 1 hour at 4°C. Cell-bound Ig was detected using 5 g/mL PE-labeled F(abЈ) 2 fragments of goat anti-human Fab-specific for 30 minutes at 4°C. F(ab) 2 -aggregated human IgG. Human IgG were incubated with PE-labeled F(abЈ) 2 fragments of goat anti-human Fab-specific for 30 minutes at 37°C and added to 2 ϫ 10 5 cells for 1 hour at 4°C.
Immune complex. Human immune complexes (ICs) were preformed by incubating 10 g/mL NIP 12 -BSA-biotin with 30 g/mL anti-NIP mAbs for 1 hour at 37°C in PBS 0.05% BSA 2 M EDTA pH7.4; 2 ϫ 10 5 cells were incubated with IC for 1 hour at 4°C. IC bound to cells were detected using neutravidin-PE at 2 g/mL for 30 minutes at 4°C.
Heat-aggregated IgG. A total of 100 g/mL human IgG were incubated in borate-buffered saline pH 8.0 for 30 minutes at 63°C, diluted to indicated concentrations in PBS 0.05% BSA, 2 M EDTA, pH 7.4, and added to 2 ϫ 10 5 cells for 1 hour at 4°C. Cell-bound IgG was detected using 5 g/mL PE-labeled F(abЈ) 2 fragments of goat anti-human Fab-specific for 30 minutes at 4°C.
Production of soluble FcR ectodomains-3xFLAG fusion protein
cDNA constructs coding for soluble FcR ectodomains tagged with a 3xFLAG peptide were transfected by a standard calcium chloride technique into HEK-293T cells. Fusion proteins from 96-hour supernatants were purified on anti-FLAG agarose beads and eluted using 3xFLAG peptide (Sigma-Aldrich). Purity of PNGase F-treated (following supplier's recommendations) or untreated proteins was assessed after SDS-PAGE and transfer onto Immobilon-P membranes (Millipore) by anti-FLAG M2-HRP (Sigma-Aldrich) blotting, revealed using ECL reagents (GE Healthcare, Little Chalfont, United Kingdom). As we failed to produce functional ectodomains of Fc␥RI, we purchased recombinant soluble C-terminal polyhistidine-tagged Fc␥RI ectodomains from R&D Systems (Minneapolis, MN).
Surface plasmon resonance analysis
A BIAcore 2000 SPR biosensor (GE Healthcare) was used to assay the interaction of soluble ectodomains of FcR with monoclonal Ig. An N-hydroxysuccinimide ester was formed on a CM5 sensor chip surface according to a procedure recommended by the manufacturer. Ectodomains were immobilized at acidic pH, resulting in the following densities: A range of Ig concentrations was injected into flow cells at a flow rate of 20L/min, with a contact and dissociation time of 300 and 900 seconds, respectively. After each assay cycle, the sensor chip surface was regenerated using 10 mM NaOH. Binding response was recorded as resonance units (RU; 1 RU Ϸ 1 pg/mm 2 ) continuously, with background binding automatically subtracted. Due to the polyclonal nature of the Ig preparations used, the kinetic constants (k on , k off , t 1/2 ) were not determined, and the K A was calculated by studying the concentration-dependence of the steady-state signal reached at the end of the injection (R eq ) using BIA evaluation version 4.2 software (GE Healthcare) and Scrubber version 2 software (BioLogic Software, Campbell, Australia). The steady-state response was plotted against the concentration of IgG and fitted using Origin software (OriginLabs, Northampton, MA) for Fc␥RI/II and for Fc␥RIII in Figures S4 and S5 (available on the Blood website; see the Supplemental Materials link at the top of the online article), respectively. Varying the densities of immobilized Fc␥R (1200-2700 RU) did not significantly affect steady-state affinities.
Results
Binding specificity of hFc␥Rs for IgG subclasses
To analyze the binding of human IgG subclasses to hFc␥Rs, a series of CHO transfectants expressing FLAG-tagged hFc␥Rs were constructed. These transfectants expressed Fc␥RI, Fc␥RIIA, Fc␥RIIB, Fc␥RIIC, Fc␥RIIIA, or Fc␥RIIIB. Multisubunit hFc␥Rs (ie, Fc␥RI and Fc␥RIIIA) were coexpressed with FcR␥. All known polymorphic variants (ie, Fc␥RIIA H131 and R131 , Fc␥RIIIA F158 and V158 , and Fc␥RIIIB NA1, NA2, and SH ) were included ( Figure S1 ). Anti-FLAG bound comparably to all transfectants, indicating that all hFc␥Rs were expressed at similar levels ( Figure 1A The binding of human IgG to transfectants was assessed by indirect immunofluorescence. Polyclonal IgG preparations (100 000g ultracentrifuged) were used to assess the binding of monomeric IgG. IgG complexed with F(abЈ) 2 anti-human F(abЈ) 2 At high concentrations (10 g/mL), IgG1-FЈ 2 IC bound to all hFc␥R but less efficiently to Fc␥RIIB and Fc␥RIIC ( Figure 2B ). IgG2-FЈ 2 IC bound to Fc␥RIIA H131 , and to Fc␥RIIA R131 and Fc␥RIIIA V158 , although less efficiently. They detectably bound to no other hFc␥R, even at higher concentrations (30 g/mL; data not shown). High concentrations of IgG3-FЈ 2 IC were not tested, as their binding exceeded the detection range. IgG4-FЈ 2 IC bound not only to Fc␥RI, but also to Fc␥RIIA, B, and C, and to Fc␥RIIIA V158 . They bound better to Fc␥RIIA R131 than to Fc␥RIIA H131 . They detectably bound neither to Fc␥RIIIA F158 nor to Fc␥RIIIB NA1, NA2, and SH , even at higher concentrations (30 g/mL; data not shown).
Altogether these results demonstrate that all 4 IgG subclasses bind to hFc␥R. IgG1 and IgG3, but not IgG2 and IgG4, bind to all hFc␥Rs (summarized in Figure 2C ). Noticeably, IgG2 bind not only to Fc␥RIIA H131 , as previously described, 33 
Influence of the FcR␥ subunit on the binding of human IgG
Unexpectedly, monomeric IgG3 could bind to the low-affinity Fc␥RIIIA V158 . This receptor can therefore function as a highaffinity FcR for one subclass of IgG. Fc␥RIIIA was previously found to have an intermediate affinity for mouse IgG2a, and this higher affinity, compared with that of other low-affinity hFc␥Rs, was proposed to rely on its association with FcR␥. 43 To investigate whether this might apply to human IgG, we generated a chimeric Fc␥RIIIA V158 whose expression would not require FcR␥ by replacing its transmembrane and intracellular domains by those of Fc␥RIIB (Fc␥RIIIA V158(EC) -IIB (TM ϩ IC) ). The binding of human polyclonal IgG was investigated on CHO transfectants expressing similar levels of FLAG-tagged human FcR␥-associated Fc␥RIIIA V158 or Fc␥RIIIA V158(EC) -IIB (TM ϩ IC) . Monomeric IgG1 (Figure S2 ), monomeric IgG2, and monomeric IgG4 (not shown) did not bind to these transfectants. Monomeric IgG3 bound similarly to both transfectants. We analyzed the behavior of heat-aggregated IgG that mimic IgG IC and that have been used in numerous FcR-binding and FcR-activation assays. Heat-aggregated IgG1, IgG2, IgG3, and IgG4 or IgG1-FЈ 2 IC and IgG3-FЈ 2 IC bound similarly to both transfectants. Fc␥RIIIA expressed independently of FcR␥ therefore has a normal affinity for human IgG.
Binding affinity of hFc␥Rs for IgG subclasses
To measure the affinity of hFc␥Rs for the 4 IgG subclasses, FLAG-tagged extracellular domains of all Fc␥RII and Fc␥RIII and their polymorphic variants were produced in HEK-293T cells. The extracellular domains of Fc␥RIIB and Fc␥RIIC being identical, a Fc␥
, was produced to analyze the affinity for Fc␥RIIB and Fc␥RIIC. Polyhistidine-tagged ectodomains of Fc␥RI were used instead of their FLAG-tagged equivalents that were not functional. These molecules were N-glycosylated as demonstrated by SDS-PAGE analysis before and after peptide:N-glycosidase F treatment (data not shown). They were covalently immobilized onto activated dextran surfaces and used for surface plasmon resonance (SPR) analysis ( Figure 3A) .
IgG1 bound to hFc␥R ectodomains with a wide range of affinity. They bound with a K A approximately 2 ϫ 10 5 M Ϫ1 to Fc␥RIIB/C and Fc␥RIIIB NA1, NA2, or SH , with a K A approximately 1.5 ϫ 10 6 M Ϫ1 to Fc␥RIIIA V158 or F158 , with a K A approximately 4 ϫ 10 6 M Ϫ1 to Fc␥RIIA H131 or R131 and with a K A approximately 6.5 ϫ 10 7 M Ϫ1 to Fc␥RI ( Figure 3A,B) .
IgG2 bound to hFc␥R ectodomains with a similarly wide range of affinities. They bound to Fc␥RIIA R131 and Fc␥RIIIA V158 with a K A approximately 8 ϫ 10 4 M Ϫ1 . They bound with a higher affinity to Fc␥RIIA H131 (K A ϭ 4.5 ϫ 10 5 M Ϫ1 ) and with a lower affinity to Fc␥RIIIA F158 and Fc␥RIIB/C (K A approximately 2.5 ϫ 10 4 M Ϫ1 ). They had no detectable affinity for Fc␥RI or Fc␥RIIIB NA1, NA2 or SH ( Figure 3A,B) .
IgG3 also bound to hFc␥R with a wide range of affinities. They bound to Fc␥RIIA H131 or R131 and to Fc␥RIIIB NA1, NA2, or SH with a K A approximately 1 ϫ 10 6 M Ϫ1 . They bound with a higher affinity (K A approximately 5 ϫ 10 6 M Ϫ1 ) to Fc␥RIIIA V158 or F158 and (K A approximately 6.1 ϫ 10 7 M Ϫ1 ) to Fc␥RI, and with a markedly lower affinity (K A ϭ 1.7 ϫ 10 5 M Ϫ1 ) to Fc␥RIIB/C ( Figure 3A,B) .
IgG4 bound to hFc␥RII/III ectodomains with a narrow range of affinities. They bound to Fc␥RIIA H131 or R131 , Fc␥RIIB/C, and Fc␥RIIIA V158 or F158 with a K A approximately 2 ϫ 10 5 M Ϫ1 . They bound with a higher affinity (K A approximately 3.4 ϫ 10 7 M Ϫ1 ) to Fc␥RI. They had no detectable affinity for Fc␥RIIIB NA1, NA2, or SH ( Figure 3A,B) .
Altogether SPR analysis data revealed that interactions of human IgG with low-affinity hFc␥Rs segregate into 2 groups: half of them have affinities of approximately 1 to a few ϫ 10 5 M Ϫ1 , half have affinities of 1 to a few ϫ 10 6 M Ϫ1 . Noticeably, Fc␥RIIB/C have the lowest affinities for all 4 IgG subclasses. Fc␥RIIA has an affinity 35-fold higher for IgG1 than Fc␥RIIB/C. Likewise, Fc␥RIIIA has an affinity 5-fold higher for IgG3 than Fc␥RIIIB. The R 131 H polymorphism affects the affinity of Fc␥RIIA for IgG2, but hardly its affinity for IgG1, IgG3, and IgG4. The F 158 V polymorphism increases moderately the affinity of Fc␥RIIIA for all 4 subclasses. The NA1/NA2/SH polymorphism does not affect the affinity of Fc␥RIIIB for any IgG subclass. As expected, Fc␥RI has the highest affinity for IgG1, IgG3, and IgG4 but has no affinity for IgG2. SPR analysis also unraveled measurable interactions of IgG2 with Fc␥RIIB/C and Fc␥RIIIA F158 and of IgG4 with Fc␥RIIIA F158 , which had not been detected by immunofluorescence analysis. For personal use only. on April 14, 2017. by guest www.bloodjournal.org From
Binding specificity of hFc␥Rs for monoclonal IgG
To determine whether hFc␥Rs have the same specificity for human monoclonal and for human polyclonal IgG, we first examined the binding of mouse/human chimeric anti-NiP antibodies having a human IgG1, IgG2, IgG3, or IgG4 Fc portion 39 to the same set of CHO transfectants as in Figure 1 . Preformed ICs were made either with NiP-BSA (IgG-Ag IC; Figure S3A ) or with F(abЈ) 2 anti-human F(abЈ) 2 (IgG-FЈ 2 IC; Figure 4A ). Higher fluorescence intensities were observed for all hFc␥Rs with IgG-FЈ 2 IC than with IgG-Ag IC. IC made with monoclonal IgG1, IgG3, and IgG4 displayed the same binding specificity for all hFc␥Rs, including polymorphic variants, as polyclonal IgG1, IgG3, and IgG4, respectively. Monoclonal IgG2 also bound similarly as polyclonal IgG2, except IgG2-Ag IC which bound weakly to Fc␥RIIB/C and Fc␥RIIIA F158 ( Figure 4A and Figure S3A ). Interestingly, a weak affinity of these 2 receptors for polyclonal IgG2 was measurable by SPR analysis ( Figure 3A,B) . When heat-aggregated or complexed with F(abЈ) 2 anti-human F(abЈ) 2 , a human myeloma IgG2 antibody, however, bound similarly and with a similar affinity as polyclonal IgG2 to Fc␥RIIIA V158 and F158 ( Figure 4B ). mAbs are increasingly used for the treatment of human diseases, such as lymphomas (anti-CD20 or anti-HLA-DR), allergic asthma (anti-IgE), or hemolytic disease of the newborn (anti-RhD). Most therapeutic mAbs are chimeric mouse/human or fully human IgG1 Abs. hFc␥Rs engaged by these mAbs remain mostly unknown. We therefore studied the binding of IgG-FЈ 2 IC made with 1 fully human IgG1 anti-RhD mAb 40 and 2 chimeric mouse/human IgG1 (anti-CD20 42 and anti-HLA-DR) to the same set of transfectants as in Figure 1 , and measured the affinity of anti-CD20 and anti-RhD for the extracellular domains of hFc␥Rs. All 3 mAbs bound to all hFc␥Rs ( Figure S3B ) with measurable affinities (Table 1 , CHO columns). Higher concentrations of complexes, however, were required for Fc␥RIIB and Fc␥RIIC, which had a lower affinity for anti-CD20 and anti-RhD than other hFc␥Rs ( Figure 5 ). Noticeably, up to 4-fold variations in affinity were observed for the 2 mAbs studied by SPR. Fc␥RIIIB polymorphisms did not detectably affect binding. Fc␥RIIA H131 and Fc␥RIIIA V158 had a higher affinity for anti-CD20 and anti-RhD than Fc␥RIIA R131 and Fc␥RIIIA F158 , respectively.
Influence of mAb fucosylation on their affinity for hFc␥Rs
The glycosylation of antibodies critically determines their ability to bind to FcRs, and glycosylation variants have been Figure 3A . The standard deviation of the affinity constant (KA) determination is indicated. For personal use only. on April 14, 2017. by guest www.bloodjournal.org From generated, aiming at enhancing their therapeutic efficacy. 44, 45 We therefore measured the affinity for hFc␥R of low-fucosecontaining anti-CD20 and anti-RhD mAbs produced in YB2/0 cells, which have decreased levels of ␣-1,6-fucosyltransferase. 46 These were compared with the same mAbs produced in ␣-1,6-fucosyltransferase-competent CHO cells (Table 1) . Fucosylation affected neither the affinity of the 2 mAbs for Fc␥RIIA and Fc␥RIIB/C, nor their higher affinity for Fc␥RIIIA V158 than for Fc␥RIIIA F158 . Fucosylation decreased the affinity of both mAbs for Fc␥RIIIA and the affinity of anti-RhD, but not of anti-CD20, for Fc␥RIIIB. Fucosylation may therefore affect the affinity of IgG1 mAbs for Fc␥RIII, but not for Fc␥RII.
Discussion
We show here that (1) IgG1 and IgG3 bind to all hFc␥Rs; (2) IgG2, which were thought to bind to Fc␥RIIA H131 only, also bind to Fc␥RIIA R131 , Fc␥RIIB, Fc␥RIIC, Fc␥RIIIA F158 , and Fc␥RIIIA V158 ; (3) IgG4, which were thought to bind to Fc␥RI only, also bind to Fc␥RIIA, Fc␥RIIB, Fc␥RIIC, and Fc␥RIIIA; and (4) the inhibitory receptor Fc␥RIIB has a lower affinity for IgG1, IgG2, and IgG3 than other hFc␥Rs. Our data establish a hierarchy of affinities of hFc␥Rs for polyclonal IgG of all 4 subclasses that could not be established from previous studies. Our data document parameters which determine the affinity of hFc␥Rs, their specificity for IgG subclasses, and how hFc␥R specificity and affinity determine the biological activities of antibodies.
They also document the role of specific hFc␥Rs in disease and therapeutics.
Fc␥Rs have been classified in 2 types, depending on their affinity for IgG. Classically, high-affinity Fc␥Rs have a K A higher than 10 7 M Ϫ1 , as measured mostly by Scatchard plot analysis, whereas low-affinity Fc␥Rs have a K A lower than 10 7 M Ϫ1 . 1 Operationally, high-affinity Fc␥Rs can bind IgG as monomers whereas low-affinity Fc␥Rs cannot. Both types of Fc␥Rs, however, can bind antigen-antibody immune complexes or IgG aggregates with a high avidity. Neither the K A threshold, which discriminates high-affinity from low-affinity Fc␥Rs, nor the lower K A , which enables low-affinity Fc␥Rs to bind IgG-immune complexes, is known. A functionally important consequence of this distinction is that low-affinity, but not high-affinity Fc␥Rs, remain free in spite of the high concentrations of circulating IgG. Affinities previously described in the literature and affinities measured in our study are difficult to compare, as the ligands and the technical approaches are different. They are, however, in the same order of magnitude (summarized in Table S1 ). From our experimental setting, we were able to define the limit between high and low-affinity for a given IgG subclass at K A approximately 9 ϫ 10 6 M Ϫ1 . Interestingly, our data show that the affinity of a given Fc␥R is not absolute but relative. It depends on the subclass of IgG. Thus, Fc␥RIIIA V158 is a high-affinity receptor for IgG3 as defined by its ability to bind monomeric IgG3 but a low-affinity receptor for IgG1, IgG2, and IgG4, as defined by its ability to bind immune complexes made of these IgG subclasses. Likewise, murine Fc␥RI has a high affinity for mouse IgG2a and a low affinity for mouse IgG2b 47 and IgG3. Our data also show that hFc␥R polymorphism differentially affects their affinity for IgG subclasses. Thus, Fc␥RIIIA V158 has a high affinity for IgG3 and a low affinity for other subclasses, whereas Fc␥RIIIA F158 has a low affinity for all 4 subclasses. Likewise, the Fc␥RIIA H 131 R mutation decreases the affinity of the receptor for IgG2 but increases the binding of IgG4. Fc␥RIIIB polymorphism affects neither the affinity nor the binding of IgG IC. Contrasting with the previous report that the FcR␥ subunit increases the affinity of Fc␥RIIIA for mouse IgG2a, 43 we found that Fc␥RIIIA expressed in the absence of FcR␥ retained the same ability as FcR␥-associated Fc␥RIIIA to bind human IgG, whatever the subclass. Finally, it is well known that unglycosylated IgG do not bind to Fc␥Rs. 48 Disialylated IgG represents only 5% of polyclonal IgG 49 and less than 3% of the monoclonal anti-CD20, anti-RhD, and anti-HLA-DR studied here; their contribution, if any, to the affinity for human Fc␥Rs could not be explored in this study. We show here that the fucosylation of monomeric IgG1 antibodies decreases their affinity for Fc␥RIIIA (and possibly Fc␥RIIIB), but not their affinity for Fc␥RIIA, Fc␥RIIB or Fc␥RIIC. These data altogether indicate that the affinity of Fc␥Rs depends not only on the receptor type but also on the polymorphism of its extracellular domains, on the IgG subclass, and on IgG glycosylation.
Fc␥Rs have been named after the class of Ig they can bind but not after IgG subclasses. 1 Human Fc␥Rs indeed display a classspecificity but no IgG subclass specificity. Noticeably, murine Fc␥Rs can display a promiscuous specificity as both IgG and IgE can bind to mFc␥RIIB, mFc␥RIIIA 50 and mFc␥RIV 47 and both IgA and IgM can bind to mFc␣/R. 51 We confirm that no human Fc␥R is specific for one IgG subclass, and we show here that most hFc␥Rs have a measurable affinity for all IgG subclasses. Two exceptions are Fc␥RI, which does not bind IgG2, and Fc␥RIIIB, Both Fc␥R specificity and affinity determine the biological activities of antibodies. Because high-affinity Fc␥Rs are occupied in vivo, but not low-affinity Fc␥Rs, these are readily available for ICs that are formed locally at a given time against a given antigen. Low-affinity Fc␥Rs are therefore more suitable than high-affinity Fc␥Rs for enabling antibodies to efficiently modulate cell responses during adaptive immune responses. Activating low-affinity hFc␥Rs are primarily Fc␥RIIA and Fc␥RIIIA. We found that Fc␥RIIA bind IgG1 with an approximately 5-fold higher affinity than IgG3. They also bind IgG2 and IgG4 with the same affinity but with an approximately 23-fold lower affinity than IgG1. We also found that Fc␥RIIIA bind IgG3 with an approximately 3-fold higher affinity than IgG1. They also bind IgG2 and IgG4, with an approximately 35-fold and an approximately 7-fold lower affinity than IgG1, respectively. These findings have the following 3 functional consequences. First, although IgG1, IgG2, and IgG4 bind each equally well to Fc␥RIIA and Fc␥RIIIA, IgG1 binds 4-to 40-fold better than IgG2 and IgG4. IgG1 can therefore engage more efficiently these 2 activating receptors than IgG2 and IgG4. Second, IgG3 bind approximately 6-fold better to Fc␥RIIIA than to Fc␥RIIA, and they bind to Fc␥RIIIA approximately 3-fold better than IgG1, approximately 100-fold better than IgG2, and approximately 24-fold better than IgG4. IgG3 can therefore preferentially engage Fc␥RIIIA and much more efficiently than IgG1, IgG2, or IgG4. This implies that IgG3 antibodies can efficiently activate Fc␥RIIIA-expressing NK cells, monocytes, and macrophages. Third, IgG2 and IgG4, which bind to Fc␥RIIA and Fc␥RIIIA, can trigger activation signals. Supporting this conclusion, IgG4 were reported to induce mediator release by polymorphonuclear neutrophils, 52 and IgG2 and IgG4 to induce cytotoxicity in PBMC. 53 We found that the inhibitory receptor Fc␥RIIB has a markedly lower affinity for IgG1, IgG2, and IgG3, but not for IgG4, than all other hFc␥Rs (except Fc␥RIIC). One can therefore wonder how Fc␥RIIB can inhibit IgG-induced cell-activation. Fc␥RIIB may be expressed at a higher density than activating hFc␥Rs on cell membranes. The relative expression of these receptors is indeed not known. It is, however, well known that Fc␥RIIB must be coengaged with activating hFc␥Rs by the same immune complex to inhibit cell activation. 54 Their concomitant binding to 2 types of receptors on the same cell can markedly enhance the binding avidity of the immune complex to coengaged Fc␥Rs. Activating hFc␥Rs may therefore "help" Fc␥RIIB to bind antibodies and to exert their inhibitory effects. As they have an identical extracellular domain as Fc␥RIIB, a reverse situation may apply to Fc␥RIIC, which is expressed on NK cells in 40% individuals. 55 Under these conditions, Fc␥RIIC may potentiate Fc␥RIIIA-dependent NK cell cytotoxicity.
hFc␥R affinity and specificity may account for recognized associations between disease and hFc␥R polymorphism. The Fc␥RIIIA V 158 F polymorphism is associated with SLE and RA. 30 Fc␥RIIIA F158 was described to bind IgG1 less efficiently than Fc␥RIIIA V158 . 20 We found that it also binds less efficiently IgG2 and IgG4. Fc␥RIIIA F158 may therefore be less efficient than Fc␥RIIIA V158 to eliminate ICs in these diseases and/or to activate inflammatory cells. Likewise, the Fc␥RIIA H 131 R polymorphism is associated with bacterial infections 17 and nephropathy. 16 We confirm that Fc␥RIIA R131 binds IgG2 IC less efficiently than Fc␥RIIA H131 . IgG2 is a major isotype in anti-bacterial antibody responses. Although Fc␥RIIIB polymorphisms have been associated with autoimmune diseases, 22, 24 we found no differences in the binding abilities of Fc␥RIIIB NA1 and Fc␥RIIIB NA2 . The association may depend on copy numbers of the gene encoding Fc␥RIIIB, as described recently. 15, 56 Finally, hFc␥R affinity is critical for antibody-based immunotherapy. The mechanism of depletion of non-Hodgkin B-cell lymphoma by anti-CD20 therapy has been linked to Fc␥Rs in humans and in mouse models (reviewed in Taylor and Lindorfer 57 ), while the mechanism of suppression induced by anti-RhD therapy in the prevention of hemolytic disease of the newborn has been shown to be both Fc␥R-dependent and -independent (reviewed in Kumpel and Elson 58 ). Oxidative bursts by myeloid cells, phagocytosis of RBC, and IL1-receptor antagonist production occurred following IgG-, but not F(abЈ)2 fragments of anti-RhD, 59 suggesting Fc␥R-dependent mechanisms. Surprisingly, mice rendered deficient for all Fc␥Rs did not affect RBC clearance, suggesting a contribution of Fc␥R-independent mechanisms, such as epitope masking. 60 Mechanisms underlying tumor killing by anti-HLA-DR IgG1 mAbs are not well identified yet, but Fc␥RI ϩ PMNs have been shown critical in ex vivo assays. 61 Our finding that IgG1 anti-CD20 antibodies or IgG1 bind less efficiently to Fc␥RIIA R131 than to Fc␥RIIA H131 may explain the lower therapeutic efficacy of rituximab in Fc␥RIIA R131 patients. 62 Our finding that IgG1 antiRhD antibodies bind less efficiently to Fc␥RIIA R131 than to Fc␥RIIA H131 and to Fc␥RIIIA F176 than to Fc␥RIIIA V176 may explain the lower clearance of RhD ϩ RBC in R/R 131 and in F/F 158 subjects. 63 Our finding that IgG4 ICs binds to Fc␥RIIA and Fc␥RIIIA may explain the "cytokine storm" that recently led to the hospitalization, due to multiple organ dysfunction, of volunteers involved in the IgG4 anti-CD28 clinical trial (TGN-412 64 ). Our finding that IgG4 is the only IgG subclass that binds equally well to Fc␥RIIB and to other hFc␥Rs supports the suspected beneficial role of IgG4 antibodies during desensitization of allergic patients. Knowing the binding selectivity of specific IgG subclasses for specific Fc␥Rs, the signaling capacity of these receptors and the function of IgG subclasses (ie, their ability to induce cell activation, phagocytosis, and cytotoxicity 65 ) will enable therapeutic antibodies to be optimized for higher efficacy and fewer side effects. 
